Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide (Equfina) effect on cognition in Parkinson's disease with/without amyloid-beta pathology
jRCTs041240076Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of safinamide in Parkinson's disease (PD), sponsored by Eisai Co., Ltd. Primary endpoint: Change in MoCA-J score from baseline to 24 weeks. Started Dec 2024; status: recruiting.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCTs041240076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240076.